Photo by meindrittesauge from unsplash
Tixagevimab and Cilgavimab (T + C) is authorized for pre‐exposure prophylaxis (PrEP) against Coronavirus Disease 2019 (COVID‐19) in solid organ transplant recipients (SOTRs), yet patient‐reported outcomes after injection are not… Click to show full abstract
Tixagevimab and Cilgavimab (T + C) is authorized for pre‐exposure prophylaxis (PrEP) against Coronavirus Disease 2019 (COVID‐19) in solid organ transplant recipients (SOTRs), yet patient‐reported outcomes after injection are not well described. Furthermore, changes in risk tolerance after T + C PrEP have not been reported, of interest given uncertain activity against emerging Omicron sublineages.
Keywords:
exposure prophylaxis;
tixagevimab cilgavimab;
pre exposure;
transplant recipients;
organ transplant;
solid organ
Journal Title: Clinical Transplantation
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Transplantation
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!